Psychiatry and Neurology, Neurology · Manati, PR
NPI
1508284936
Since 2014
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
0
Hospital affiliations
Manati Medical Center Professional Plaza Ofic. 611, Calle Hernandez Carrion
Manati, PR, 00674
Phone (787) 621-3755
Groups this clinician bills Medicare through
Medicare paid, 2024
$14K
209 services
Medicare patients, 2024
39
Average age 74
Drug cost, 2024
$3.1M
8,030 prescriptions
Company payments, 2025
$18K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Laura S Surillo-Dahdah was code 99441 (telephone services), 45 times for 28 patients. In total Laura S Surillo-Dahdah billed 209 services in 22 codes, and Medicare paid $14K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99441 Telephone Services | Office | 45 | 28 | $35.00 | $1,575 |
| 99213 Office E&M - Established | Office | 33 | 21 | $68.92 | $2,274 |
| 99214 Office E&M - Established | Office | 21 | 18 | $95.31 | $2,001 |
By year: 2022 $13K for 145 services; 2023 $13K for 171 services; 2024 $14K for 209 services.
Medicare prescription drug claims, 2024
In 2024, the drug Laura S Surillo-Dahdah prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 1,312 prescriptions and refills. In total Laura S Surillo-Dahdah wrote 8,030 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 1,312 | 1,640 | 278 | $61K |
| Rytary Carbidopa/Levodopa | 1,228 | 1,265 | 153 | $862K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 342 | 428 | 77 | $14K |
| Memantine Hcl Generic | 320 | 373 | 62 | $4,944 |
| Gabapentin Generic | 290 | 327 | 63 | $3,168 |
| Donepezil Hcl Generic | 279 | 357 | 73 | $2,272 |
| Amantadine Amantadine Hcl | 265 | 305 | 54 | $13K |
| Primidone Generic | 229 | 263 | 55 | $11K |
| Baclofen Generic | 185 | 187 | 49 | $2,921 |
| Carbidopa-Levodopa-Entacapone Carbidopa/Levodopa/Entacapone | 168 | 196 | 33 | $26K |
| Mirtazapine Generic | 167 | 192 | 38 | $4,135 |
| Topiramate Generic | 164 | 196 | 43 | $1,869 |
| Neupro Rotigotine | 158 | 160 | 31 | $140K |
| Nuplazid Pimavanserin Tartrate | 139 | 139 | 22 | $714K |
| Rivastigmine Rivastigmine Tartrate | 137 | 163 | 34 | $6,741 |
Brand drugs: 2,156 claims; generic drugs: 5,874 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Laura S Surillo-Dahdah $18K ($18K in general payments such as food, travel and fees) from 11 companies. The largest payer was Abbvie Inc. with $9,394.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 14 | $9,394 |
| Amneal Pharmaceuticals LLC AMRX | 18 | $7,809 |
| ACADIA Pharmaceuticals Inc ACAD | 17 | $335 |
| Teva Pharmaceuticals USA, Inc. TEVA | 2 | $137 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $131 |
| MDD US Operations, LLC | 2 | $54.4 |
| Pfizer Inc. PFE | 2 | $45 |
| SK Life Science, Inc. | 1 | $32.74 |
| Biogen, Inc. BIIB | 1 | $26.39 |
| Medtronic, Inc. MDT | 1 | $19.57 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.